Global Microbiome Therapeutics Market Analysis 2020 & Forecasts 2021-2026: Market to Grow from $141.7 million in 2021 to $1.3 Billion by 2026, at a CAGR of 56.4% - ResearchAndMarkets.com
The global market for microbiome therapeutics should grow from $141.7 million in 2021 to $1.3 billion by 2026, at a compound annual growth rate (CAGR) of 56.4% for the period of 2021-2026.
GIT diseases market for microbiome therapeutics should grow from $87.9 million in 2021 to $222 million by 2026, at a CAGR of 20.4% for the period of 2021-2026.
Infections diseases market for microbiome therapeutics should grow from $53.8 million in 2021 to $191.8 million by 2026, at a CAGR of 28.9% for the period of 2021-2026.
This report provides a comprehensive analysis of the microbiome therapeutics market in global context, including market forecasts and sales through 2025.
The report analyzes the market by segmenting it into the various types of microbiome therapeutics, based on the strategies used for treatment: additive (fecal matter transplants or FMTs, live biotherapeutic products or LBPs), modulatory (postbiotics, prebiotics) and subtractive microbiome therapeutics (phages and antimicrobials).
This study surveys the microbiome therapeutics market by application or disease segments: infectious diseases, metabolic diseases, cancer, gut-brain axis and others. The market is also assessed in the following geographic regions: North America, Europe and emerging markets. Emerging markets include countries like India, China, Korea, Taiwan, Africa, Australia, New Zealand, Canada and Latin America.
The report features leading clinical trials indicating the status and phase of development. New developments and patents are boosting the growth of this market in the global context.
The report provides comprehensive profiles of market players in the industry. The industry structure chapter focuses on the changing market trends, market players and their leading pipeline candidates. This chapter also covers the mergers and acquisitions and any other collaborations or partnerships that happened during the evaluation period of this report that are expected to shape the industry.
Factors such as strengths, weaknesses, threats and opportunities that are expected to play a role in the microbiome therapeutics market are evaluated in detail.
Excluded from this report are the markets for prebiotics and probiotics labeled as nutritional or dietary supplements. Prebiotics and probiotics, if included, only pertain to when used in the context of microbiome therapy.
The report includes:
An in-depth overview of the global microbiome therapeutics market
Analyses of the global market trends, with data corresponding to market size for 2021-2025, and projections of compound annual growth rates (CAGRs) through 2026
Latest information on market drivers and opportunities, challenges and restraints, technological developments, and regulatory updates, along with their impact on the stakeholders in this market
Evaluation of market potential for microbiome therapeutics market, their market share analysis on the basis of product types, applications, and regions
Highlights of this innovation driven microbiome therapeutics market covering current trends, disease areas of application, clinical trials and their stages, and new developments
Impact of COVID-19 pandemic on the global economy and delay in the clinical trial activity and financial effects on the overall growth of this market
Competitive landscape of this market featuring leading biopharmaceutical companies, their products pipeline and company share analysis
Key merger and acquisition deals, collaborations and partnerships, licensing and manufacturing agreements, and other notable investment strategies within this market
Patent review and deep-dive of the issued patents on the basis of categories such as type, year, disease type, company, country, and assignee
Profile description of the major market participants, including Azitra Inc., Evelo Biosciences, LNC Therapeutics, Second Genome and Vedanta Biosciences Inc.
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
The Human Microbiome
The Different Microbiomes in Humans
Microbiome and Human Health and Disease
Technologies Aiding Microbiome Research
Microbiome Research Projects
Microbiome Therapeutics
Strategies for Development of Microbiome Therapeutics
Microbiome Therapeutics Disease Areas
Regulatory Landscape for Microbiome Therapeutics
Chapter 4 Market Breakdown by Technology Type
Market by Microbiome Strategy Type
Market Overview
Additive Microbiome Therapeutics
Modulatory Microbiome Therapeutics
Subtractive Microbiome Therapeutics
Chapter 5 Market Breakdown by Application
Market by Disease Type
Market Overview
Market Revenue
Market Shares
Infections
Gastrointestinal (GIT) Diseases
Metabolic Diseases
Cancer
Gut-Brain Axis Diseases
Other Diseases
Market by Region
Market Shares
Chapter 6 Industry Structure
Investment in Microbiome Therapeutics
Public Funding Initiatives
Private Funding Initiatives
Collaborations and Partnerships
Licensing and Manufacturing Agreements
Mergers and Acquisitions
Leading Market Players in Microbiome Therapeutics Market
Leading Market Players in Additive Microbiome Therapeutics Market
Leading Market Players in Modulatory Microbiome Therapeutics Market
Leading Market Players in Subtractive Microbiome Therapeutics Market
Select Insights from Industry Leaders
Chapter 7 Patent Analysis
Patent Analysis
Patents by Year
Patents by Type
Patents by Disease Type
Patents by Company
Patents by Country
Patents by Assignee
Chapter 8 Clinical Trial Analysis
Clinical Trial Analysis by Disease Category
Clinical Trial Analysis by Treatment Strategy
Clinical Trial Analysis by Company
Microbiome Therapeutics in Discovery and Preclinical Development
Microbiome Therapeutics Clinical Trials in Phase 3
Chapter 9 Analysis of Market Opportunities
SWOT Analysis
Strengths of Microbiome Therapeutics Market
Challenges for Microbiome Therapeutics Market
Opportunities for Microbiome Therapeutics Market
Threats to the Microbiome Therapeutics Market
Chapter 10 Company Profiles
4D Pharma
AO Biome LLC
Armata Pharmaceuticals
Assembly Biosciences Inc.
Azitra Inc.
Biomica
Biomx
Chain Biotechnology Ltd.
Eligo Bioscience SAS
Enterome SA
Evelo Biosciences
Finch Therapeutics Group Inc.
Intralytix Inc.
Kaleido Biosciences
Kintai Therapeutics Inc.
LNC Therapeutics Inc.
MaaT Pharma
Osel Inc.
Pylum Bioscienes Inc.
Quorum Innovations LLC
Rebiotix Inc. (Acquired by Ferring Pharmaceuticals)
As the final Intergovernmental Negotiating Body (INB) meeting of the World Health Organization (WHO) Pandemic Agreement approaches, the AIDS Healthcare Foundation and the AHF Global Public Health Institute are voicing significant concerns about the...
Tractor Beverage Company, one of North America's fastest-growing beverage brands and the first and only Certified Organic, non-GMO beverage company devoted to the food service industry, was named the winner of a Gold Stevie® Award in the Products in...
E-Textile Market is Segmented by Type (Passive Electronic Textiles, Active Electronic Textiles, Ultra-Electronic Textiles), by Application (Military Uses, Civil Uses, Healthcare Uses).
The Global E-Textile Market size is expected to reach USD 5238.3...
The Law Offices of Frank R. Cruz reminds investors of the upcoming April 29, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II...
Leading research and experience management firm Sogolytics has released an original study examining the telehealth landscape, highlighting its achievements and challenges in providing positive experiences for patients.
"It's critical for providers...
The "North America Dry Mix Mortar Market - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America)" report has been added to ResearchAndMarkets.com's offering....